Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study

Table 3 Baseline laboratory results and treatments of the studied 125 patients

	mean ± SD/n (%)
Pulse rate	92 ± 17
Temperature	37 ± 1
Respiratory rate	23 ± 5
Oxygen saturation	93 ± 5
Hemoglobin (gm/dL)	12 ± 2
Platelet count (× 1000/cmm)	183 ± 107
Total leucocyte count (× 1000/cmm)	10 ± 8
Neutrophil : Lymphocyte ratio	1 ± 0
INR	1.16 ± 0.29
PTT	33.9 ± 13.2
Serum creatinine (mg/dL)	1.39 ± 1.43
Serum sodium (mEq/L)	137 ± 9
Serum potassium (mEq/L)	4.18 ± 0.77
Total bilirubin (mg/dL)	3 ± 5
Direct bilirubin (mg/dL)	2.1 ± 3.8
Serum albumin (g/dL)	3.2 ± 0.7
Alanine Transaminase (U/L)	58 ± 53
Aspartate Transaminase (U/L)	92 ± 123
Alkaline phosphatase (U/L)	262 ± 226
Serum ferritin (ng/mL)	667 ± 483
D-dimer (mg/mL)	1560 ± 2503
Fibrinogen (mg/dL) × 100 if presented in g/L	77
Azithromycin	72 (57.6)
Paracetamol	45 (36.0)
Supplementary vitamin C	85 (68.0)
Zinc	69 (55.2)
Colchicine	2 (1.6)
Lactoferrin	18 (14.4)
Other antibiotics	71 (56.8)
Steroids	38 (30.4)
Hydroxyl-chloroquine	29 (23.2)
Low-molecular weight heparin	56 (44.8)
Warfarin	3 (2.4)

PTT: Partial thromboplastin time; INR: International normalized ratio.